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R E S E A R C H  A R T I C L E
Bromodomain and Extraterminal Inhibition by JQ1 
Produces Divergent Transcriptional Regulation of 
Suppressors of Cytokine Signaling Genes in Adipocytes
Paula Mota de Sá,1,2 Allison J. Richard,1 and Jacqueline M. Stephens1,2
1Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808; 
and 2Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803
ORCiD numbers: 0000-0002-9559-4061 (A. J. Richard).
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway 
has cell-specific functions. Suppressors of cytokine signaling (SOCS) proteins are negative-
feedback regulators of JAK-STAT signaling. STAT5 plays a significant role in adipocyte 
development and function, and bromodomain and extraterminal (BET) proteins may be involved 
in STAT5 transcriptional activity. We treated 3T3-L1 adipocytes with the BET inhibitor JQ1 and 
observed that growth hormone (GH)-induced expression of 2 STAT5 target genes from the SOCS 
family, Socs3 and Cish, were inversely regulated (increased and decreased, respectively) by BET 
inhibition. Chromatin immunoprecipitation analyses revealed that changes in STAT5 binding did 
not correlate with gene expression changes. GH promoted the recruitment of the BET protein 
BRD2 to the Cish, but not Socs3, promoter. JQ1 treatment ablated this effect as well as the GH-
induced binding of ribonucleic acid polymerase II (RNA Pol II) to the Cish transcription start site. 
BRD2 knockdown also suppressed GH induction of Cish, further supporting the role of BRD2 
in Cish transcriptional activation. In contrast, JQ1 increased the binding of activated Pol II to 
the Socs3 coding region, suggesting enhanced messenger RNA (mRNA) elongation. Our finding 
that JQ1 transiently reduced the interaction between the positive transcription elongation factor 
(P-TEFb) and its inhibitor hexamethylene bis-acetamide inducible 1 (HEXIM1) is consistent with 
a previously described off-target effect of JQ1, whereby P-TEFb becomes more available to be 
recruited by genes that do not depend on BET proteins for activating transcription. These results 
demonstrate substantially different transcriptional regulation of Socs3 and Cish and suggest 
distinct roles in adipocytes for these 2 closely related proteins. (Endocrinology 161: 1–15, 2020)
Key Words:  growth hormone, STAT5, adipocytes, BET proteins, P-TEFb, HEXIM1
S ignal transducers and activators of transcription (STATs) are a family of transcription factors ex-
pressed in most cells and tissues. In mammals, there 
are 7 members in the family (STATs 1, 2, 3, 4, 5A, 5B, 
and 6), which are activated by different ligands, de-
pending on cell type. Upon external stimulation, STATs 
dimerize in the cytosol and translocate to the nucleus 
where they control the expression of target genes (1). 
The suppressors of cytokine signaling (SOCS) family 
has 8 members, SOCS1 through SOCS7 and cytokine-
inducible SH2-containing protein (CISH), all of which 
are well-established STAT target genes. These proteins 
are rapidly transcribed and translated following Janus 
kinase-signal transducer and activator of transcription 
Abbreviations: ANOVA, analysis of variation; BET, bromodomain and extraterminal; 
CALF, bovine calf serum; CISH, cytokine-inducible SH2-containing protein; cDNA, 
complementary DNA; DMEM, Dulbecco’s Modified Eagle Media; DMSO, Dimethyl 
sulfoxide;  DNA, deoxyribonucleic acid; FBS, fetal bovine serum; GH, growth 
hormone; GHR, GH receptor; HEXIM1, hexamethylene bis-acetamide inducible 
1; HIV, human immunodeficiency virus; IP, immunoprecipitation; JAK, Janus kin-
ase; KD, knockdown; m, mouse; mRNA, messenger RNA; NT, nontargeting; Pol II, 
polymerase II; P-TEFb, positive transcription elongation factor; qPCR, quantitative 
polymerase chain reaction; RNA, ribonucleic acid; RT, reverse transcription; SEC, 
super elongation complex; SDS, sodium dodecyl sulfate; Ser2, serine 2; siRNA, 
small interfering RNA; SOCS, suppressors of cytokine signaling; STAT, signal trans-
ducer and activator of transcription; TSS, transcription start site.
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(JAK-STAT) pathway activation, and they function to 
turn off JAK-STAT signaling via a negative feedback 
loop (2). In adipocytes, growth hormone (GH) or pro-
lactin can activate STAT5 (3, 4), and a number of studies 
have demonstrated that this transcription factor is im-
portant for adipocyte development and function (5). 
The regulation of important physiological processes, 
such as carbohydrate and lipid metabolism, by GH is, 
at least in part, accomplished by its effects on gene tran-
scription (6). For example, GH can upregulate insulin 
growth factor 1 in the liver and other tissues, including 
adipose tissue (7, 8). Conversely, GH-induced binding 
of STAT5 to the promoter of B-cell lymphoma 6 (BCL6) 
gene inhibits its expression (9).
Bromodomain and extraterminal (BET) proteins 
(BRDT, BRD2, BRD3, and BRD4) are epigenetic readers 
that bind to acetylated histones and promote transcrip-
tion, forming a link between chromatin remodeling 
and transcription factors. BETs can recruit the positive 
transcription elongation factor b (P-TEFb), a cyclin-
dependent kinase composed of 2 cyclin-dependent 
kinase 9 catalytic subunits and 2 regulatory subunits, 
which are usually cyclin T1 (10). P-TEFb phosphoryl-
ates the C-terminal domain of ribonucleic acid poly-
merase II (RNA polymerase II) on serine 2 (Ser2), an 
essential modification for transcription elongation (11). 
Inhibition of BET proteins by small molecules has been 
extensively studied for treating cancer (12–14) and in-
flammatory states (15, 16). BET inhibition is generally 
associated with reduced transcriptional activation and, 
consequently, with decreased gene expression. Notably, 
however, studies have shown that gene transcription of 
human immunodeficiency virus (HIV)-1 is dependent 
on P-TEFb (17) and can be increased by BET inhib-
ition (18, 19). This upregulation is explained by a sec-
ondary effect of BET inhibitors to release P-TEFb from 
its inhibitory complex so that it is more available for 
transcript elongation (18, 20). In normal cellular con-
ditions, where inducible genes contain Pol II poised at 
their promoters, elongation is tightly regulated by the 
equilibrium between inactive P-TEFb that is associated 
with the scaffold 7SK noncoding RNA and HEXIM1 
(hexamethylene bis-acetamide inducible 1) and a free ac-
tive form of P-TEFb that can be recruited by other pro-
teins including BRD4 and the super elongation complex 
(SEC) (18). BET proteins have also been shown to be 
involved in STAT5 transcriptional activity (14, 21) and 
may, therefore, play a role in the regulation of STAT5 
target genes in adipocytes.
The goal of our study was to examine how BET 
inhibition would affect the ability of GH to regulate 
STAT5 target genes using murine 3T3-L1 adipocytes 
as a model system. The effects of the BET inhibitor 
JQ1 were opposite for 2 members of the SOCS family. 
GH-mediated upregulation of Cish was decreased by 
BET inhibition, while induction of Socs3 was substan-
tially increased. Chromatin immunoprecipitation ana-
lysis demonstrated that changes in STAT5A binding to 
the promoter region of these genes did not necessarily 
correlate with changes in gene expression. We observed 
that the BET protein BRD2 was recruited to the Cish 
promoter by GH and that this recruitment was de-
creased by JQ1. Moreover, BRD2 knockdown (KD) de-
creased GH induction of Cish, further supporting the 
dependency of Cish transcriptional activation on this 
BET protein. In contrast, the upregulation of Socs3 by 
JQ1 was attributed to enhanced mRNA elongation. 
BET inhibitors have been reported to release P-TEFb 
from its inhibitory complex and upregulate HEXIM1 
(18). In our study, the BET inhibitor JQ1 transiently de-
creased the interaction between the regulatory subunit 
of P-TEFb (Cyclin T1) and HEXIM1, rendering more 
of the elongation factor available for recruitment to the 
Socs3 promoter. Our data underscore the complexity of 
the transcriptional effects of epigenetic modulators and 




Murine 3T3-L1 preadipocytes (originally obtained 
from lab H, Green lab at Harvard Medical School) 
were grown to 2 days after confluence in Dulbecco’s 
Modified Eagle Media (DMEM; Sigma-Aldrich, St. 
Louis, MO) with 10% bovine calf serum (CALF). 
Cells were induced to differentiate using a standard 
MDI induction cocktail of 0.5  mM 3-isobutyl-1-
methylxanthine  (MIX), 1  μM dexamethasone, and 
1.7 μM insulin in DMEM containing 10% character-
ized fetal bovine serum (FBS). Cell identity was con-
firmed for each group of cells by monitoring their 
ability to differentiate into adipocytes, which contain 
lipid droplets that can be observed via phase-contrast 
microscopy. HyClone CALF and FBS were purchased 
from Thermo Scientific or GE Healthcare Life Sciences 
(Logan, UT). The medium was changed every 48 to 
72 hours during all phases of growth and differen-
tiation. When specified, cells were serum deprived 
with DMEM containing 0.3% bovine serum albumin 
(BSA; Cat #: A6003, Sigma-Aldrich, St. Louis, MO). 
Otherwise, cells were serum deprived by changing the 
media to DMEM containing 1% CALF for 16 to 24 
hours before treatment with the inhibitor. (+)-JQ1 
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Recombinant murine GH was purchased from Dr A.F. 
Parlow at the National Hormone and Peptide Program 
(NHPP; Torrance, CA).
Antibodies
Antibodies against BRD2 (22) (D89B4; rabbit mono-
clonal), lamin B1 (23) (D4Q4Z; rabbit monoclonal), 
and rabbit IgG (24) (2729; rabbit polyclonal) were 
purchased from Cell Signaling Technology (Danvers, 
MA). Anti-RNA Pol II CTD repeat YSPTSPS (pS2) 
(25) (ChIP grade ab5095; rabbit polyclonal), cyclin 
T1 (26) (ab184703; rabbit monoclonal), HEXIM1 
(27) (ab25388; rabbit polyclonal), STAT5A (28) 
(E289; rabbit monoclonal; for WB Cat# ab32043; for 
ChIP Cat#: ab213219) were purchased from Abcam 
(Cambridge, MA). Anti-BRD4 (29) (PA5-41550; 
rabbit polyclonal) was purchased from ThermoFisher 
Scientific (Waltham, MA). Anti-histone H3 (30) (06-
599; rabbit polyclonal), histone H4 (31) (06-866; 
rabbit polyclonal), RNA Pol II (32) (17-620; mouse 
monoclonal) and control mouse IgG were purchased 
from Millipore Sigma (Burlington, MA).
Reverse transcription–quantitative polymerase 
chain reaction
Total RNA was purified from harvested 3T3-L1 adipo-
cyte monolayers using the RNeasy mini kit from Qiagen 
(Hilden, Germany). RNA levels were quantified by spec-
trophotometry. Complementary deoxyribonucleic acid 
(cDNA) was synthesized by reverse transcription (RT) 
with the High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA), according to the 
manufacturer’s protocol. Genes of interest were quanti-
fied by real-time quantitative PCR (qPCR) using Takara 
SYBR Premix (Takara Bio USA, Mountain View, CA) 
and the Applied Biosystems 7900HT Fast Real-Time 
PCR System. Cyclophilin a and NoNo were used as ref-
erence genes. The following mouse (m) genes were exam-
ined by RT-qPCR: mCyclophilin a, mNoNo, mSocs3, 
mCish, mBcl6, mIgf1, mSocs2, mBrd2, mHexim1 using 
primers purchased from Integrated DNA Technologies 
(IDT, Skokie, IL). Primer sequences for each gene are 
shown in Table 1.
Chromatin immunoprecipitation 
The medium on mature 3T3-L1 adipocytes (7–15 days 
post-MDI) was replaced with 1% CALF for 16 to 24 
hours. Following a 30-minute pretreatment with JQ1 or 
dimethyl sulfoxide (DMSO) (control), cells were treated 
with vehicle or GH for 30 minutes. DNA-protein 
crosslinking, nuclear preparation, chromatin digestion, 
and chromatin immunoprecipitation (ChIP) assays were 
performed using the SimpleChIP kit (Magnetic Beads) 
from Cell Signaling Technology (Cat #: 9003S; Danvers, 
MA) according to the manufacturer’s instructions. For 
each ChIP, 8 to 12  μg of digested, cross-linked chro-
matin were incubated with the following amounts of 
antibodies, as recommended by their respective manu-
facturers: rabbit anti-STAT5A (28) (2 μg), mouse anti-
RNA Pol II (32) (1 μg), rabbit anti-phosphoserine2 RNA 
Pol II (25) (4 μg), rabbit anti-BRD2 (22) 1:50 dilution, 
rabbit BRD4 (29) (1 μg), rabbit ac-histone H3 (5 μL), 
rabbit ac-histone H4 (5  μL), nonimmune IgG control 
antibody rabbit IgG (24) from ChIP kit (2 μg) or mouse 
IgG from RNA Pol II kit (1  μg). After protein diges-
tion and DNA purification using the columns provided 
in the SimpleChIP kit, input and immunoprecipitated 
DNA samples were analyzed using real-time qPCR on 
the Applied Biosystems 7900HT Fast Real-Time PCR 
System. We used the qPCR amplification program spe-
cified in the kit instructions with the exception that the 
initial denaturation step was performed for 10 minutes 
at 95°C. We also added a dissociation curve step at the 
end of the reaction. Primers used to amplify different 
regions of the Cish and Socs3 genes are described in 
Table 2. A standard curve prepared with only 2% input 
samples and 5-fold serial dilutions was made to assess 
amplification efficiency.
IP efficiency was calculated using the percent 
input approach and the following equation: Percent 
Table 1. Primers Used for RT-qPCR
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input = 2% × 2(C[T] 2% Input Sample– C[T] Input Sample); where 
C[T] = threshold cycle of the PCR reaction. Percent input 
of control rabbit and mouse IgG was calculated for all 
the regions analyzed and ranged from 0.03% to 0.1%. 
The coding regions of Socs3 and Cish were used as con-
trol regions lacking STAT binding sites. STAT5-specific 
Figure 1. Regulation of STAT5 target genes by GH. Mature 3T3-L1 adipocytes were treated with 5 nM GH in triplicate and harvested at indicated 
time points. Relative gene expression of Socs3, Cish, Igf1, Socs2, and Bcl6 were quantified by RT-qPCR using cyclophilin a as the housekeeping 
gene. This experiment was replicated at least 3 times in different batches of cells. Data are presented as means ± SE (n = 3 per treatment). All 
time points are compared to time 0. Statistical significance was determined using one-way ANOVA. *P < 0.05, **P < 0.005, ***P < 0.001, 
****P < 0.0001. Abbreviations: ANOVA, analysis of variance; GH, growth hormone; RT-qPCR, reverse transcription–quantitative polymerase chain 
reaction; SE, standard error; STAT, signal transducer and activator of transcription. 
Table 2. Primers Used for ChIP-qPCR
Gene Region Forward Reverse
Cish SBS 5’-CGTCCAGCGATACGATTGGT-3’ 5’-CAGGCGTCTAGTGCTTTGGA-3’
Cish TSS 5’-GTTCGCACCACAGCCTTTCAGTCC-3’ 5’-TGCCAGGGGTGCGAAGGTCAGG-3’
Cish Coding 5’-TACCCCTTCCAACTCTGACTGAGC-3’ 5’-TTCCCTCCAGGATGTGACTGTG-3’
Socs3 SBS 5’-GCACAGCCTTTCAGTGCAGAG-3’ 5’-GTATTTACCCGGCCAGTACGC-3’
Socs3 TSS 5’-GCGTACTGGCCGGGTAAATAC-3’ 5’-GGAGAGACAGCGGTCGTAAG-3’
Socs3 Coding 5’-CATTTAGAAGGGAGACAGATGAG-3’ 5’-CATAGGAGAGACAAAGCAGAAC-3’
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binding was at least 50-fold higher at Cish promoter 
and 30-fold higher at Socs3 promoter when compared 
with the nonspecific coding region or for nonimmune 
IgG binding at the same sites. BRD2 binding to Cish 
promoter was 10-fold higher than binding to the coding 
region, while BRD2 binding to Socs3 promoter was 
only 2-fold higher than binding to the coding region.
Preparation of whole-cell extracts
Cell monolayers were rinsed once with phosphate buf-
fered saline and then scraped into nondenaturing IP buffer 
that contained 10  mM Tris (pH 7.4), 150  mM NaCl, 
1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-
tetraacetic acid (EGTA), 1 mM ethylenediaminetetraacetic 
acid (EDTA), 1% Triton X-100, 0.5% IGEPAL CA-630, 
protease inhibitors (1  mM phenylmethylsulfonyl 
fluoride  [PMSF], 1  μM pepstatin, 50 trypsin inhibi-
tory milliunits of aprotinin, 10  μM leupeptin, 1mM 1, 
10-phenanthroline), and phosphatase inhibitors (100 μM 
sodium fluoride and 0.2 mM sodium vanadate). The cell 
suspension was subjected to a freeze/thaw cycle at –80°C 
and then passed through a 20-gauge needle 5 times. 
The whole-cell extract was clarified by centrifugation at 
13 000 × g for 10 minutes at 4°C.
Measurement of protein concentration
Protein content of cell and tissue extracts was de-
termined using the bicinchoninic acid assay kit from 
Sigma-Aldrich (Cat #: BCA1).
Gel electrophoresis and immunoblotting
Samples were separated on 6% or 7.5% sodium 
dodecyl sulfate (SDS) polyacrylamide gels (acrylamide, 
Cat #: EC-890, from National Diagnostics, Atlanta, 
GA) and transferred to nitrocellulose membranes (Cat 
#: 162-0115, BioRad, Hercules, CA). Results were visu-
alized with horseradish peroxidase-conjugated sec-
ondary antibodies (Jackson ImmunoResearch, West 
Grove, PA) and enhanced chemiluminescence (Pierce/
Thermo Scientific, Rockford, IL).
Small interfering RNA-mediated knockdown
3T3-L1 mature adipocytes (5–7 days post-MDI) were 
trypsinized from 6-well plates and re-plated in 12-well 
plates at a density of 1.16 × 105 cells/cm2 in antibiotic-
free medium (10% FBS/DMEM). Adipocytes were trans-
fected using DharmaFECT Duo reagent (Dharmacon; 
Cat #: T-2010-03) and 50  nM of nontargeting (NT; 
Cat #: D-001810-10-50) or Brd2 (Cat #: L-043404-
00-0005) small interfering RNA (siRNA) in OptiMEM 
reduced serum medium (Thermo Fisher; Cat #: 
31985088). Twenty-four hours later, siRNA-containing 
media was removed and replaced with antibiotic-free 
10% FBS/DMEM. After 24 hours, adipocytes were 
transfected again with NT or Brd2 siRNA.  siRNA-
containing medium was removed 24 hours later and re-
placed with 10% FBS. After 24 hours, FBS was replaced 
by 1% CALF, antibiotic-free. The next day, cells were 
treated with vehicle or 5 nM GH for 1 hour. Adipocytes 
were harvested in RLT buffer (Qiagen) for RNA ana-
lysis, and whole-cell extracts were collected in IP buffer 
for protein quantification.
Immunoprecipitation 
Cell extracts (300 μg total protein) were incubated 
with 5  μl of anti-cyclin T1 antibody overnight on a 
mini-tube rotator at 4°C. Protein A-conjugated agarose 
(IPA300 Protein A  Resin; Cat #: 10-2003-02) from 
Repligen (Waltham, MA) or Protein A/G Plus-agarose 
(Cat #: sc-2003) beads from Santa Cruz Biotechnology 
(Dallas, TX) were added to the antibody-epitope mix-
ture. The conjugation reaction continued for an add-
itional 1 to 2 hours at 4°C with rotation. Next, the 
beads were pelleted by centrifugation at 13  000  rpm 
for 3 minutes at 4°C. The supernatant was removed 
by aspiration, and the beads were washed 3 times with 
ice-cold 1X IP buffer containing protease inhibitors. 
Between each wash, the beads were pelleted by centri-
fugation at 12  000  rpm for 1 minute at 4°C and the 
supernatant removed by aspiration. After the final wash, 
the IP antibody and immunoprecipitated proteins were 
eluted from the bead resin into 2X SDS loading buffer 
by boiling the samples for 10 minutes at 100°C. Samples 
were flicked multiple times during the heat step to en-
sure efficient elution. The samples were briefly centri-
fuged and the supernatants analyzed by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and immunoblotting. A mock sample containing a pool 
of equal concentration of all samples and no IP antibody 
was used as a negative control to ensure that there was 
no unspecific binding of the beads to protein samples.
Statistical analysis
Data were plotted as mean ± standard error (SE). The 
qPCR data were analyzed using either using one-way 
analysis of variation (ANOVA) or two-way ANOVA. For 
ChIP experiments, data were analyzed using two-way 
ANOVA with the Bonferroni post hoc test. Differences 
with P < 0.05 were considered statistically significant.
Results
GH regulation of STAT5 target genes in 
adipocytes
In order to study the modulation of STAT5 target 
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and harvested at different time points, up to 48 hours. 
The expression of STAT5 target genes was analyzed 
by RT-qPCR (Fig.  1). As expected, Socs3 and Cish 
were acutely regulated by GH treatment. The induc-
tion of Socs3 mRNA was evident at 30 minutes, and 
the maximal response was observed at one hour. Cish 
was upregulated at one hour and remained elevated 
after 48 hours. Bcl6 expression was downregulated by 
GH at early time points and remained low over the 
course of treatment. Socs2 and Igf1 were also induced 
by GH, but at later time points. Since Socs3 and Cish 
are well characterized in other model systems (33–37) 
and were acutely induced by GH at early time points, 
we focused our additional studies on these 2 STAT5 
target genes.
BET inhibition increased GH-induced Socs3 
expression and decreased GH-induced Cish 
expression
The thienotriazolodiazepine JQ1 competitively binds 
to bromodomains of BET proteins and prevents their 
binding to chromatin. Only (+)-JQ1 interacts with 
bromodomains; the enantiomer (−)-JQ1 does not inhibit 
BET proteins (38). As shown in Fig. 2A, BET inhibition 
using the active enantiomer (+)-JQ1 decreased GH in-
duction of Cish and increased Socs3 upregulation in a 
dose-dependent manner. In addition, the effects of JQ1 
on GH induction of Cish and Socs3 were acute, as only 
30 minutes of pretreatment were sufficient to produce 
these opposite effects on Cish and Socs3 expression 
(Fig. 2B). The effects of BET inhibition decreased over 
time, probably because of JQ1’s short half-life (39). In 
vehicle conditions, there were no statistically significant 
differences between treatments.
GH recruits BRD2 to the Cish promoter, and JQ1 
decreases BRD2 and RNA Pol ll recruitment
Since GH treatment induces the JAK-STAT signaling 
pathway and STATs modulate transcription of target 
genes, we investigated the effects of JQ1 on binding of 
various transcriptional regulators to distinct sites in the 
promoters or coding sequences of the Socs3 or Cish 
genes. Fig.  3A illustrates the 3 target regions of Cish 
that were amplified by qPCR: one region containing 
STAT binding sites (SBS), another containing the tran-
scription start site (TSS), and a third within the coding 
region of Cish. Results demonstrated that GH and JQ1 
each modestly increased STAT5A binding to the Cish 
Figure 2. JQ1 upregulates Socs3 and downregulates Cish. (A) Mature 3T3-L1 adipocytes were pretreated for 30 minutes with JQ1 at different 
concentrations. Vehicle or 5 nM of GH were added 1 hour before the cells were harvested. (B) Mature adipocytes were pretreated with 1 μM JQ1 
for indicated times, and vehicle or 5 nM of GH were added 1 hour before the cells were harvested. Gene expression levels were quantified by 
RT-qPCR. Cyclophilin a was used as the reference gene. Data are presented as means ± SE (n = 3 per treatment). This experiment was replicated 
3 times in different batches of cells. Treatments were normalized to vehicle condition in the absence of inhibitor. Statistical significance was 
determined using two-way ANOVA. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001. Abbreviations: ANOVA, analysis of variance; GH, 
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Figure 3. Recruitment of RNA Pol II to Cish TSS highly correlates to BRD2 recruitment. (A) Schematics of Cish regions that were amplified by qPCR 
in ChIP assay, including STAT binding site, transcription start site (TSS) and coding region of the gene. (B-F). Mature adipocytes were pretreated 
with 2 μM JQ1 or DMSO for 30 minutes. Next, cells were treated with vehicle (V; NaHCO3) or 5 nM GH for 35 minutes. Chromatin was cross-linked 
using formaldehyde, and nuclear extracts were subjected to ChIP using specific antibodies. The amount of bound DNA was measured by qPCR and 
percentage input was calculated. IP efficiency (% input) of (B) STAT5A binding to STAT binding site, (C) BRD2, (D) BRD4, (E) total RNA polymerase 
II, (G) ac-histone H3, (H) ac-histone H4 binding to Cish TSS and (F) RNA Pol IIpS2 binding to Cish coding region. This experiment was replicated 
3 times in different batches of cells. Statistical significance was calculated using two-way ANOVA and the Bonferroni post hoc test. * denotes 
significance among V and GH in the presence or absence of JQ1. # denotes significance between DMSO and JQ1 in the presence or absence 
of GH. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001; #P < 0.05, ###P < 0.005, ###P < 0.001, ####P < 0.0001. Abbreviations: ANOVA, 
analysis of variance; ChIP, chromatin immunoprecipitation; DMSO, dimethyl sulfoxide; GH, growth hormone; Pol II, polymerase II, RNA, ribonucleic 
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STAT binding site (Fig. 3B), but that JQ1 had no further 
effect on STAT5A binding in the presence of GH. As 
BRD4 is the most well-studied BET protein and BRD2 
was previously described to be involved in STAT5 tran-
scriptional regulation (14, 21), binding of BRD2 and 
BRD4 to the Cish TSS was also investigated. BRD2 was 
recruited to Cish TSS by GH, and its binding was sup-
pressed by JQ1 (Fig.  3C). BRD4 binding levels were 
low, ranging from 0.06% to 0.2% input, only slightly 
higher than IgG levels ranging from 0.03% to 0.1% 
input (data not shown). In addition, BRD4 binding 
was not substantially altered by GH or JQ1 treatment 
(Fig. 3D). As expected, total RNA Pol II binding to Cish 
TSS was increased by GH treatment. In the presence of 
JQ1, this RNA Pol II recruitment to Cish TSS was de-
creased (Fig. 3E). Similarly, the binding of Pol II phos-
phorylated at Ser2, a marker of RNA elongation, to 
the coding region of Cish was increased with GH and 
suppressed by JQ1 (Fig. 3F). Since BET proteins bind to 
acetylated histones, we also assessed the levels of total 
acetylated histone H3 (Fig. 3G) and H4 (Fig. 3H) at the 
Cish TSS. In the presence or absence of JQ1, GH highly 
increased ac-histone H3 and H4 at the Cish promoter. 
JQ1 further increased only ac-histone H4 in the pres-
ence of GH.
JQ1 increases Socs3 mRNA elongation
Fig. 4A illustrates the 3 target regions of Socs3 that 
were amplified by qPCR. STAT5A interaction with its 
binding site in Socs3 was strongly enhanced by GH but 
minimally affected by JQ1 treatment, indicating that the 
effect of JQ1 on GH-induced Socs3 expression was not 
the result of increased STAT5A binding (Fig. 4B). In con-
trast to what we observed at the Cish TSS, BRD2 was 
not recruited to the Socs3 TSS by GH, and JQ1 mod-
estly decreased its binding (Fig. 4C). BRD4 binding to 
the Socs3 TSS was somewhat higher than binding to the 
Cish TSS, but it was not substantially affected by GH or 
JQ1 (Fig. 4D). RNA Pol II recruitment to the Socs3 TSS 
was increased by GH; JQ1 enhanced Pol II recruitment 
in the vehicle condition but had no effect in GH condi-
tions (Fig. 4E). Therefore, changes in BRD2 or RNA Pol 
II recruitment to the Socs3 promoter did not explain the 
greater upregulation of Socs3 expression by JQ1 either. 
Binding of activated Pol II to the Socs3 coding region, 
however, was robustly increased by JQ1, suggesting that 
the upregulation of Socs3 gene expression by JQ1 is due 
to augmented mRNA elongation (Fig.  4F). Acetylated 
histone H3 (Fig. 4G) and H4 (Fig. 4H) levels were much 
lower at Socs3 TSS when compared to Cish. In add-
ition, neither GH nor JQ1 had any notable influence on 
acetylated histone H3 levels. GH increased ac-histone 
H4 only in the presence of JQ1.
BRD2 knockdown decreases GH activation 
of Cish
Our ChIP experiments demonstrated that BRD2 
was recruited to the Cish promoter by GH, and JQ1 
decreased this recruitment. To determine whether the 
effects of JQ1 were dependent on BRD2, we used an 
siRNA KD approach. Fig.  5A shows mRNA levels of 
Brd2, Socs3, and Cish. KD efficiency at the mRNA 
level was about 50%. In basal conditions, neither 
Cish nor Socs3 expression was affected by Brd2 KD. 
However, only GH activation of Cish was reduced by 
Brd2 KD, further supporting the hypothesis that BRD2 
is necessary for GH activation of Cish. In contrast, the 
upregulation of Socs3 by JQ1 was not recapitulated by 
BRD2 KD, ruling out the possibility that BRD2 was 
acting as a negative regulator of Socs3. BRD2 protein 
levels were decreased by about 80% in the KD condi-
tions versus the NT control, and GH had no effect on 
BRD2 protein expression (Fig. 5B).
JQ1 interferes with P-TEFb availability and 
upregulates HEXIM1
To explain why JQ1 upregulates Socs3, we scoured 
the literature for examples of genes upregulated by BET 
inhibition. Curiously, JQ1 was reported to upregulate 
HIV-1 expression through the transient release of 
P-TEFb from its inhibitory complex, leading to com-
pensatory upregulation of HEXIM1 (18). To investigate 
if this could occur for GH-induced Socs3 transcription, 
we treated 3T3-L1 adipocytes with DMSO or JQ1 for 
2, 6, or 24 hours and examined Hexim1, Socs3, and 
Cish gene expression. Interestingly, JQ1 substantially 
upregulated Hexim1; levels peaked at 6 hours and 
started to decrease at 24 hours but remained signifi-
cantly higher than in the DMSO control. Adipocytes 
were also treated with GH for 1 hour before harvesting 
for induction of Socs3 and Cish and for confirmation 
of inhibitor effects (Fig. 6A). In addition, we measured 
HEXIM1 protein levels at the same time points and ob-
served a progressive accumulation of HEXIM1 when 
the cells were treated with JQ1. We also found that JQ1 
upregulated BRD2 protein levels. Quantification and 
fold change of BRD2 and HEXIM1 using cyclin T1 as a 
control is shown below the Western blot images (Fig. 6B). 
Lastly, cell lysates were immunoprecipitated with cyclin 
T1 antibody (the regulatory portion of P-TEFb) to 
evaluate the impacts of JQ1 on P-TEFb availability. In 
Fig. 6C, quantification values of BRD2 and HEXIM1 
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Figure 4. Socs3 mRNA elongation is enhanced by JQ1. (A) Schematics of Socs3 regions that were amplified by qPCR in ChIP assay, including 
STAT binding site, transcription start site (TSS), and coding region of the gene. (B-F). Mature adipocytes were pretreated with 2 μM JQ1 or DMSO 
for 30 minutes. Next, cells were treated with vehicle (V; NaHCO3) or 5 nM GH for 35 minutes. Chromatin was cross-linked using formaldehyde, 
and nuclear extracts were subjected to ChIP using specific antibodies. The amount of bound DNA was measured by qPCR and percentage input 
was calculated. IP efficiency (% input) of (B) STAT5A binding to STAT binding site, (C) BRD2, (D) BRD4, (E) total RNA polymerase II (Pol II), (G) 
ac-histone H3, (H) ac-histone H4 binding to Cish TSS, and (F) RNA Pol IIpS2 binding to Cish coding region. This experiment was replicated 3 
times in different batches of cells. Statistical significance was calculated using two-way ANOVA and the Bonferroni post hoc test. * denotes 
significance among V and GH in the presence or absence of JQ1. # denotes significance between DMSO and JQ1 in the presence or absence of 
GH. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001; #P < 0.05, ###P < 0.005, ###P < 0.001, ####P < 0.0001. Abbreviations: ChIP, chromatin 
immunoprecipitation; DMSO, dimethyl sulfoxide; DNA, deoxyribonucleic acid; mRNA, messenger ribonucleic acid; qPCR, quantitative polymerase 







/endo/article/161/2/bqz034/5686880 by Louisiana State U
niversity user on 05 August 2021
10  Mota de Sá et al.  Divergent Regulation of Socs Genes Endocrinology, XXXX 2020, 161(2):1–15
Figure 5. BRD2 knockdown (KD) downregulates growth hormone (GH)-induction of Cish and has no effect on Socs3 expression. Fully 
differentiated 3T3-L1 adipocytes were transfected with 50 nM nontargeting (NT) siRNA or Brd2 siRNA. siRNA-containing media was removed 
24 hours later and replaced with 10% FBS. After 48 hours, adipocytes were transfected again with NT or Brd2 siRNA. siRNA-containing 
media was removed 24 hours later and replaced with 10% FBS. After 24 hours, FBS was replaced by 1% CALF. The next day, cells were 
treated with vehicle (NaHCO3) or 5 nM murine growth hormone (GH) for 1 hour. (A) Cells were collected in RLT lysis buffer (Qiagen). Total 
RNA was isolated and subjected to RT-qPCR analysis. Brd2, Socs3 and Cish mRNA levels were measured. Nono was used as the reference 
gene. (B) Whole-cell extracts were collected in IP buffer, and 30 μg of protein was used for gel electrophoresis. BRD2 and lamin B1 protein levels 
were detected by Western blot. Band intensities were quantified and fold change was calculated by dividing BRD2/lamin B2 and is represented 
below Western blot images. Data are presented as means ± SE (n = 3 per treatment). This experiment was replicated 2 times in different batches of 
cells. Statistical significance was determined using two-way ANOVA. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 for comparisons 
of NT versus Brd2 KD. Abbreviations: ANOVA, analysis of variance; CALF, bovine calf serum; FBS, fetal bovine serum; IP, immunoprecipitation; 
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the Western blot images. For the 2-hour JQ1 treatment, 
the interaction between cyclin T1 and HEXIM1 was 
reduced, while interaction with BRD2 was increased. 
As the interaction with HEXIM1 increased over time, 
the interaction with BRD2 decreased. The highest in-
crease in Socs3 expression occurs at 2 hours for JQ1 
treatment, when the interaction between HEXIM1 and 
cyclin T1 is maximally inhibited. As HEXIM1 protein 
levels increase and P-TEFb complex is reassembled, the 
JQ1-induced increase in GH-activated Socs3 expression 
decreases. These results confirmed that JQ1 has an off-
target effect on P-TEFb availability in adipocytes.
Discussion
The transcription factor STAT5 has been extensively 
studied for its pathophysiological roles in cancer because 
its constitutive activation can lead to dysregulation of cell 
development and survival (40–43); it is also known to 
play an important role in fat cell development and func-
tion (5, 44, 45). However, the exact molecular mechan-
isms by which STAT5 impacts cell fate and physiology 
are still poorly understood. The BET protein, BRD2, has 
been reported to be involved in STAT5-mediated tran-
scription (14, 21). In our investigation, treatment of adi-
pocytes with the BET inhibitor JQ1 produced divergent 
effects on 2 well-known STAT5 target genes. GH activa-
tion of Cish was reduced, while activation of Socs3 was 
even greater in the presence of JQ1 (Fig. 2).
Figure 6. JQ1 transiently upregulates Hexim1 expression and decreases its interaction with cyclin T1. (A) Mature adipocytes were treated with 
DMSO or 2 μM JQ1 for 2, 6, or 24 hours. Cish, Socs3, and Hexim1 gene expression levels were quantified by RT-qPCR. Nono was used as the 
reference gene. Samples were normalized to controls treated with DMSO (JQ1 vehicle) and NaHCO3 (GH vehicle). Data from GH-treated samples 
are shown and presented as means ± SE (n = 3 per treatment). Statistical significance was calculated using two-way ANOVA with the Bonferroni 
post hoc test. * denotes significance among DMSO and JQ1 treatment. # denotes significance between 2 hours and the other time points. 
*P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001; #P < 0.05, ###P < 0.005, ###P < 0.001, ####P < 0.0001. (B) 3T3-L1 mature adipocytes 
were treated with 2 μM JQ1 for the indicated time points. Control (CTL) cells were untreated. Whole-cell extracts were collected in IP buffer, and 
25 μg of protein was used for gel electrophoresis. HEXIM1, BRD2, and cyclin T1 protein levels were detected by Western blot. (C) From the same 
experiment as B, 300 μg of total protein was incubated with anti-cyclin T1 antibody overnight. Interacting HEXIM1 and BRD2 were detected 
by Western blot. The mock sample was composed of a pool of all samples without any antibody. For B and C, band intensities were quantified 
and cyclin T1 was used as a loading control to calculate fold change. Quantification graphs are shown below immunoblot images. Statistical 
significance was calculated using one-way ANOVA. * denotes significance between CTL and other treatments as described for A. Abbreviations: 
ANOVA, analysis of variance; DMSO, dimethyl sulfoxide; GH, growth hormone; RT-qPCR, reverse transcription–quantitative polymerase chain 







/endo/article/161/2/bqz034/5686880 by Louisiana State U
niversity user on 05 August 2021
12  Mota de Sá et al.  Divergent Regulation of Socs Genes Endocrinology, XXXX 2020, 161(2):1–15
ChIP was used to investigate the interaction of BET 
proteins, STAT5, and RNA Pol II with the Socs3 and 
Cish promoters, as well as the enrichment of RNA Pol 
II phosphorylated at Ser2 on Socs3 and Cish coding re-
gions. Changes in STAT5 binding were similar for both 
genes, indicating that this was not driving the divergent 
gene expression patterns (Figs 3B and 4B). Binding of 
both BRD2 and RNA Pol II to the Cish TSS was in-
creased by GH and suppressed by the BET inhibitor JQ1 
(Fig. 3C and E). We therefore hypothesized that BRD2, 
which is required for GH-induced Cish transcription, 
was displaced from the TSS by JQ1, thus affecting RNA 
Pol II recruitment and consequently decreasing the 
ability of GH to induce Cish gene expression. Since BET 
proteins bind to acetylated histones, we also assessed 
histone H3 and H4 acetylation at the Socs3 and Cish 
promoters and observed higher total acetylation levels 
at the Cish (Fig. 3G and H) promoter compared with 
Socs3 (Fig. 4G and H). In addition, at basal conditions, 
GH increased acetylation at the Cish, but not the Socs3, 
TSS (transcription start site). These results support the 
hypothesis that GH induction of Cish gene expression is 
dependent on increased acetylation at the promoter to 
facilitate the recruitment of BRD2 to acetylated lysines 
at the Cish TSS. In the presence of JQ1, BRD2 binding 
is decreased and may consequently affect recruitment 
of the basal transcription machinery. This phenomenon 
has been similarly described for interleukin-3 activation 
of Cish in Ba/F3 cells (21). BRD2 involvement in GH ac-
tivation of Cish was further confirmed by the observed 
reduction in Cish expression when BRD2 was knocked 
down using siRNA (Fig. 5A).
BRD2 was not recruited to the Socs3 promoter by 
GH, and BET inhibition had only minor effects on 
BRD2 binding to the Socs3 TSS (Fig.  4C), suggesting 
that BRD2 is not required for GH-regulated Socs3 
expression. RNA Pol II recruitment to Socs3 was en-
hanced by JQ1 in basal conditions, but not in the 
presence of GH (Fig. 4E). On the other hand, enrich-
ment of phosphorylated Pol II to the coding region of 
Socs3 was highly augmented by JQ1 (Fig.  4F). Since 
RNA Pol II phosphorylated at Ser2 is a well-known 
marker of elongation, we concluded that JQ1 increases 
Socs3 mRNA elongation. Although we did not directly 
measure the binding of the elongation factor P-TEFb to 
Cish or Socs3 promoters, we know that RNA Pol II is 
primarily phosphorylated at Ser2 by P-TEFb in meta-
zoans (46).
The upregulation of Socs3 by JQ1 was at first chal-
lenging to explain; however, extensive work done in 
the HIV field has shed light on how the inhibition of 
BET proteins could upregulate some genes. In fact, the 
phenomenon does not necessarily involve BET proteins 
but may instead constitute an off-target effect whereby 
JQ1 (18) and other BET inhibitors (47) induce the re-
lease of P-TEFb from its inhibitory complex. HEXIM1 
acts to inhibit P-TEFb when they are both associated 
with 7SK small nuclear RNA (48). In our experiments, 
the decreased association between cyclin T1 (the regu-
latory subunit of P-TEFb) and HEXIM1 following 
JQ1 exposure coupled with the increased association 
between BRD2 and cyclin T1 (Fig. 6C), as well as the 
upregulation of HEXIM1 (Fig. 6B), support the hypoth-
esis that JQ1 interferes with the binding of P-TEFb to its 
inhibitory complex. Disruption of the P-TEFb inhibitory 
complex increases P-TEFb availability and also activates 
cellular feedback mechanisms to upregulate HEXIM1 
expression and reassemble the 7SK small nuclear RNA 
inhibitory complex (18, 49). Nonetheless, our findings 
do not exclude the possibility that the upregulation of 
Socs3 by JQ1 is not a direct effect on HEXIM1–P-TEFb 
interaction, and other modulators of mRNA elongation 
might be affected by BET inhibition.
Most studies have focused on BRD4 interaction with 
the P-TEFb complex via its cyclin T1 subunit. Our study 
confirms that BRD2 can also be present in a complex 
with cyclin T1. Further investigation will be required to 
determine whether this interaction is direct or mediated 
by other proteins. Among all BETs, only BRD4 possesses 
a C-terminal segment called P-TEFb interacting domain 
that can actively dissociate P-TEFb from HEXIM1. But 
depletion of that domain does not completely eliminate 
the association between BRD4 and cyclinT1 (50, 51), 
indicating that another region of BET proteins may fa-
cilitate this interaction.
Our results support the model shown in Fig. 7 where 
the upregulation of Socs3 by JQ1 is due to interfer-
ence with the P-TEFb inhibitory complex. While more 
studies will be needed to fully explain the divergent 
transcriptional regulation of Socs3 and Cish, our hypo-
thetical model suggests that GH upregulation of Cish is 
dependent on BRD2 recruitment to the promoter and 
on recruitment of RNA Pol II and P-TEFb for transcript 
elongation. When JQ1 is present, it displaces BRD2 
from the Cish promoter, thus decreasing its gene expres-
sion. GH upregulation of Socs3, on the other hand, is 
likely dependent on another factor. Since P-TEFb, when 
not bound to its inhibitory complex, is reported to asso-
ciate with either BRD4 or the SEC (19, 52, 53), we hy-
pothesize that SEC is responsible for recruiting P-TEFb 
to the Socs3 promoter. When JQ1 is present, it disrupts 
the interaction between P-TEFb and HEXIM1, allowing 
more P-TEFb to be available for recruitment by SEC, 
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SOCS3 and CISH are members of the suppressors 
of the cytokine signaling family. All members of this 
family possess a conserved Src homology 2 domain and 
a C-terminal SOCS box. The Src homology 2 domain 
inhibits the signaling pathway via direct or competi-
tive binding to phosphorylated intermediates, while the 
SOCS box can associate with ubiquitination machinery 
that targets proteins to the proteasome for degradation 
(54). Studies comparing SOCS proteins have revealed 
different mechanisms of inhibition among the family 
members. SOCS3 and SOCS1 possess a kinase inhibi-
tory region (55) that is responsible for Janus kinase 
(JAK) inhibition. SOCS3 can also bind simultaneously 
to JAK and cytokine receptors, revealing higher levels 
of specificity (56, 57). On the other hand, CISH does 
not interact with JAKs. The binding of CISH to more 
distal tyrosine residues of the growth hormone receptor 
(GHR) leads to direct competition with STAT5 binding 
sites. Alternatively, CISH is involved in a proteasome-
dependent mechanism that may induce GHR internal-
ization and destruction of GHR–JAK2–CISH complexes 
(6, 58).
Differences in the activation patterns of Socs3 and 
Cish have been described (34, 37), and we have con-
firmed these differences in our studies. The fast and acute 
upregulation of Socs3, with activation peaking between 
30 minutes and 1 hour and a return to basal levels in 2 
hours, represents a classical feedback loop. Cish, however, 
is upregulated a little later and remains highly elevated 
even after 48 hours of GH stimulation. Therefore, despite 
similar protein structures and roles in inhibiting cytokine 
signaling pathways, differences in gene activation pat-
terns and divergent responses to BET inhibition demon-
strate that Socs3 and Cish may have different functions, 
at least in the context of cultured murine adipocytes.
The role of BET proteins in epigenetics and gene regu-
lation has been an intensive area of research. Preclinical 
studies have shown that the BET inhibitor OTX015 af-
fects JAK/STAT signaling and can increase Hexim1 ex-
pression (59), suggesting an off-target effect on P-TEFb 
regulation. Moreover, OTX015, is now in a phase 1b 
clinical trial in patients with selected advanced solid 
tumors (60). The results of our study also suggest an 
off-target effect of JQ1 on P-TEFb regulation that influ-
ences STAT5 target gene expression in adipocytes. The 
possibility that BET inhibitors affect the availability of 
P-TEFb, the primary regulator of mRNA elongation, has 
potentially broad biological consequences and should 
be taken into consideration when these drugs are con-
sidered for therapeutic use. Furthermore, the fact that 2 
Figure 7. Model for potential differences between Socs3 and Cish gene expression. Under normal conditions, when 3T3-L1 adipocytes are 
stimulated with GH, the JAK-STAT signaling pathway is activated. STAT5 dimerizes and binds to STAT binding sites within the Cish and Socs3 
promoters. For the Cish promoter, BRD2 is recruited by GH treatment. Then, BRD2 binds acetylated histones and recruits the positive elongation 
factor (P-TEFb), which is composed of 2 CDK9 and 2 cyclin T1 subunits. P-TEFb is responsible for the phosphorylation of Ser2 on the RNA Pol II 
C-terminal domain (CTD) to promote elongation. When the cells are pretreated with JQ1 before GH stimulation, BRD2 is displaced from chromatin. 
Therefore, P-TEFb is not recruited to Cish promoter. At the Socs3 promoter, GH treatment stimulates the recruitment of P-TEFb by another 
factor, possibly the super elongation complex (SEC). P-TEFb then phosphorylates RNA Pol II and productive elongation occurs. When the cells are 
pretreated with JQ1, in addition to release of BRD2 from chromatin, it also releases P-TEFb from its inhibitory complex. P-TEFb then becomes more 
available to promote Socs3 elongation. Abbreviations: GH, growth hormone; JAK, Janus Kinase; RNA Pol II, ribonucleic acid polymerase II; Ser2, 
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very similar genes, Cish and Socs3, utilize different tran-
scriptional machinery, resulting in such opposite regula-
tion in the presence of JQ1, demonstrates how unique 
and complex the regulation of GH-induced gene expres-
sion is and may have important implications in the feed-
back regulation of JAK/STAT signaling in adipocytes.
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